SGLT2 inhibitors have been repeatedly shown by several studies to improve ANP secretion in patients with newly diagnosed T2DM, delay elevation of BNP in older patients with T2DM, and improve renal function due to reduction of BNP levels (20–22). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.